INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.990
+0.020 (1.02%)
Sep 16, 2025, 10:06 AM EDT - Market open
INmune Bio Revenue
INmune Bio had revenue of $50.00K in the twelve months ending June 30, 2025, down -41.18% year-over-year. In the year 2024, INmune Bio had annual revenue of $14.00K, down -90.97%.
Revenue (ttm)
$50.00K
Revenue Growth
-41.18%
P/S Ratio
1,047.46
Revenue / Employee
$2,273
Employees
22
Market Cap
52.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INMB News
- 5 weeks ago - INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment - GlobeNewsWire
- 6 weeks ago - INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th - GlobeNewsWire
- 7 weeks ago - INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference - GlobeNewsWire
- 2 months ago - INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's - Seeking Alpha
- 2 months ago - 'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
- 2 months ago - INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain - Benzinga